Question 1

What is peptidenews.us?

Accepted Answer

PeptideNews.us is an independent news aggregator that tracks the latest peptide and GLP-1 research, FDA regulatory updates, enforcement actions, clinical studies, vendor pricing, and community discussions — updated 4 times daily.

Question 2

What peptides does Peptide News cover?

Accepted Answer

Peptide News covers over 150 peptides including BPC-157, TB-500, Semaglutide (Ozempic/Wegovy), Tirzepatide (Mounjaro/Zepbound), GLP-1 agonists, GHK-Cu, PT-141, Ipamorelin, CJC-1295, Thymosin Alpha-1, Sermorelin, Retatrutide, Epitalon, and many more.

Question 3

How often is Peptide News updated?

Accepted Answer

Peptide News automatically scrapes and aggregates content from dozens of sources 4 times daily — at 00:00, 06:00, 12:00, and 18:00 UTC — ensuring you always have the most current peptide and GLP-1 news.

Question 4

Does Peptide News cover FDA enforcement actions?

Accepted Answer

Yes. Peptide News has a dedicated Enforcement Alerts tab that tracks FDA warning letters, seizures, raids, arrests, indictments, CBP/US Customs actions, and carrier (USPS, FedEx, UPS) enforcement related to peptides and compounding pharmacies.

Question 5

What is the 503B compounding pharmacy situation with peptides?

Accepted Answer

503B outsourcing facilities are FDA-regulated compounding pharmacies that can legally produce peptides like semaglutide and tirzepatide under certain conditions. Peptide News tracks all FDA regulatory changes, crackdowns, and enforcement actions affecting 503B compounders in real time.

Sign in to view your account